Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

8.19USD
15 Dec 2017
Change (% chg)

$-0.32 (-3.76%)
Prev Close
$8.51
Open
$8.61
Day's High
$8.61
Day's Low
$8.19
Volume
6,481
Avg. Vol
24,907
52-wk High
$17.99
52-wk Low
$5.81

Latest Key Developments (Source: Significant Developments)

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article

ARCTURUS, SYNTHETIC GENOMICS ANNOUNCE ALLIANCE TO DEVELOP VACCINES, THERAPEUTICS
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Synthetic Genomics::ARCTURUS THERAPEUTICS AND SYNTHETIC GENOMICS ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT-GENERATION VACCINES AND THERAPEUTICS.UNDER COLLABORATION, CO WILL HAVE EXCLUSIVE ACCESS TO LUNAR TECHNOLOGY FOR VACCINES AND THERAPEUTICS, USING SELF-AMPLIFYING RNA​.UNDER, COLLABORATION, ‍ARCTURUS WILL RECEIVE UPFRONT CASH PAYMENT, RESEARCH AND DEVELOPMENT SUPPORT, PRE-CLINICAL, DEVELOPMENT, SALES MILESTONE PAYMENTS.‍UNDER COLLABORATION, ARCTURUS WILL ALSO RECEIVE ROYALTY PAYMENTS ON ANY FUTURE SUBLICENSED PRODUCTS ​.  Full Article

Alcobra Ltd Q2 loss per share $0.13
Friday, 11 Aug 2017 08:00am EDT 

Aug 11 (Reuters) - Alcobra Ltd :Alcobra announces second quarter 2017 financial results and provides corporate update.Qtrly loss per share $0.13.Announced that it had engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for process.Also exploring best path forward with its clinical assets, ADAIR and MDX ,including monetization and partnering.Company has also taken significant action to streamline its operations in order to preserve capital, including a 65% reduction in force.As part of recent reduction in force, Jonathan Rubin, co's chief medical officer, will be stepping down effective September 11, 2017.Appointed two new directors, Mr. Amir Efrati and Mr. Yuval Yanai, to Alcobra board of directors..  Full Article

Alcobra establishes special committee to explore, evaluate strategic alternatives
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Alcobra Ltd ::Alcobra updates on its review of strategic alternatives.Says ‍company also intends to streamline its operations in order to preserve its capital and cash resources​.Says ‍board has established a special committee to explore and evaluate strategic alternatives​.Alcobra - is continuing to assess best path forward for its abuse-deterrent amphetamine immediate-release (Adair), metadoxine extended release (MDX) clinical programs.Alcobra Ltd says ‍potential strategic alternatives that may be explored include potential for an acquisition, merger, business combination.Alcobra Ltd says ‍potential strategic alternatives that may be explored also include other strategic transaction involving company​.Says ‍engaged Ladenburg Thalmann & Co Inc to act as its strategic financial advisor for strategic alternatives​ process.  Full Article

Alcobra announces cooperation agreement with Brosh Group
Monday, 12 Jun 2017 08:36am EDT 

June 12 (Reuters) - Alcobra Ltd ::Alcobra announces cooperation agreement with Brosh Group and board additions.Alcobra Ltd says company to continue strategic alternatives process.Alcobra Ltd - appointed two new directors, Amir Efrati and Yuval Yanai, to Alcobra board of directors.Alcobra Ltd - as of 2 new appointments, alcobra board consists of ten directors.Alcobra Ltd - cooperation agreement also provides that co will continue its ongoing review of strategic alternatives.Company's upcoming AGM will be postponed until september 1, 2017.Alcobra Ltd - entered into a cooperation agreement with Brosh Capital Partners L.P. and certain of its affiliates.Alcobra ltd - under terms of agreement, Brosh Group is subject to certain customary standstill and other provisions.  Full Article

Alcobra reports Q1 loss per share $0.13
Tuesday, 30 May 2017 08:00am EDT 

May 30 (Reuters) - Alcobra Ltd :Alcobra announces first quarter 2017 financial results and provides corporate update.Alcobra Ltd qtrly loss per share $0.13.Alcobra Ltd says IND application for its amphetamine immediate release product candidate is expected to be filed with U.S. FDA in Q3 of this year.Alcobra Ltd says continues to evaluate strategic opportunities to expand its pipeline and enhance value for all its shareholders.  Full Article

Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group
Friday, 5 May 2017 12:43pm EDT 

May 5 (Reuters) - Alcobra Ltd ::Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group.Reached an agreement with Brosh Capital L.P. and certain of its affiliates on cancellation of extraordinary general meeting of shareholders.Extraordinary general meeting will be cancelled, Brosh Group shall withdraw its related meeting notice and proxy materials.Alcobra will convene its annual general meeting no later than July 20, 2017.Parties agreed co will bring to a shareholder vote any merger/acquisition deal which it enters into prior annual general meeting.Brosh to refrain from initiating proceedings/taking action for convening of any meeting of shareholders until convening of co's annual general meeting.  Full Article

Amir Efrati says reports 16.8 pct stake in Alcobra as of April 12
Wednesday, 12 Apr 2017 08:59am EDT 

Alcobra Ltd : Amir Efrati - on April 12, delivered notice to Alcobra to convene independent extraordinary general meeting of shareholders - SEC filing . Amir Efrati - on April 12, responded to Alcobra’S letter dated April 5, rejecting reasoning for not convening extraordinary general meeting .Amir Efrati says reports 16.8 percent stake in Alcobra Ltd as of April 12.  Full Article

Amir Efrati reports 16.8 pct stake in Alcobra Ltd
Monday, 10 Apr 2017 04:57pm EDT 

Alcobra Ltd : Amir Efrati reports 16.8 percent stake in Alcobra Ltd as on April 6, 2017 .Amir Efrati had previously reported 12 percent stake in alcobra ltd as on March 31, 2017.  Full Article

Amir Efrati reports passive stake of 9 pct in Alcobra Ltd
Friday, 24 Feb 2017 05:40pm EST 

Alcobra Ltd : Amir Efrati reports passive stake of 9 percent in alcobra ltd as on Feb. 22, 2017 .Amir Efrati had previously reported passive stake of 7.5 percent in Alcobra Ltd as of Jan. 23, 2017.  Full Article